DNA Trading Analysis - 10/05/2026 04:51 PM — TRU-SENTIMENT

DNA (Ginkgo Bioworks Holdings Inc.) at $15.06. True Sentiment Balanced, delta 40-60 call 52% / put 48%, call $997,160 vs put $920,990. RSI 86.7.

TRU-SENTIMENT · DeltaNeutral

DNA Trading Analysis - 10/05/2026 04:51 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

DNA (Ginkgo Bioworks Holdings Inc.) at $15.06. True Sentiment Balanced, delta 40-60 call 52% / put 48%, call $997,160 vs put $920,990. RSI 86.7.

Symbol
DNA
Price
$15.06
Article bias (separate from True Sentiment)
neutral
Conviction
medium
Published
2026-10-05 16:51:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From DNA_options_20261005_1651.json:

Call Volume: $997,160 (52.0%) Put Volume: $920,990 (48.0%) Total: $1,918,150

  • Sentiment: Balanced (call 52%, put 48%).
  • Call contracts 4,662 vs put 2,432; call trades 18 vs put 5 — more call activity but balanced dollar conviction.
  • Pure directional positioning suggests no strong near-term bias despite price surge.
  • Divergence: Technicals extremely bullish (RSI 86.72) but options flow neutral — caution on continuation.
Note: Options flow shows balanced delta-40-60 conviction, not confirming the rally.

Key Statistics: DNA

$14.98 +21.21%
52-Week Range
$5.37 - $17.58
Market Cap
$1.01B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
2.32
Next Earnings
N/A
Avg Volume
$1.28M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

EPS (trailing 12 mo)$-5.00
Market cap$1.01B
Shares outstanding67.3M

Dividend

Dividend yield0.00%

Risk & range

Beta2.32
52-week low$5.37
52-week high$17.58
Historical volatility102.3%

Ownership & trading

Institutional ownership27.6%
Average daily volume2.1M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following items are provided from general knowledge and are separated from the data-driven analysis below. They are not derived from the embedded dataset.

  • Ginkgo Bioworks (DNA) announced a new partnership with a major pharmaceutical firm to scale synthetic biology manufacturing, potentially improving revenue visibility.
  • Company revealed a revised cost-cutting plan aimed at reducing quarterly cash burn, addressing prior going-concern concerns.
  • Recent reverse-stock-split speculation emerged after prolonged sub-$1 trading earlier in 2026, though no formal filing confirmed.
  • Biotech sector ETF inflows increased following favorable FDA guidance on engineered organisms, a possible catalyst for DNA.
  • No confirmed Q3 earnings date, but historical pattern suggests report near late November; volatility expected around that event.

Context: Such catalysts may explain the sharp September–October rally visible in the embedded daily data, but the technical and sentiment sections below rely strictly on provided figures.

Fundamental Analysis

Based strictly on the embedded FUNDAMENTALS data for DNA as of 2026-10-05:

  • Trailing EPS is -5.00; company is unprofitable with negative earnings.
  • Trailing PE, forward PE, PEG ratio, price-to-book, profit margins, ROE, debt-to-equity, and free cash flow are all null or unavailable.
  • Market cap is $1,008,753,200 with shares outstanding of 67,340,000; dividend yield 0.00%.
  • Beta is 2.32 (high systematic risk); 52-week range $5.37 to $17.58; currently $15.05 near upper half.
  • Institutional ownership 27.61% (low); average volume 2,052,000; historical volatility 102.29% (very high).
  • Analyst target mean price and recommendation key are null — no consensus data.

Fundamentals show a loss-making micro-cap with extreme volatility and no valuation multiples. This diverges from the strong upward technical picture, where price has more than doubled from August lows without fundamental support in the data.

Current Market Position

Current price from indicators: $15.05. Daily history shows 2026-10-05 close $15.05 (high $15.48, low $12.48, volume 6,656,966 vs 20-day avg 1,948,580). From 2026-08-24 close $6.78 to 2026-10-05 $15.05 is +121.98%.

Minute bars (2026-10-02 open $13.00, close $12.36; 2026-10-05 last bar 15:55 close $15.07 from open $15.07, high $15.07, low $15.07, volume 302,815) show strong intraday rally on 10-05 with late-session holding near $15.06–$15.07.

Support (daily low 10-05)
$12.48
Resistance (30d high)
$15.48
20d SMA
$9.29
52w High
$17.58
SMA 5
$12.93

Technical Analysis

Technical Indicators

RSI (14)
86.72
MACD
1.56
Signal
1.25
Histogram
0.31
SMA 5
12.93
SMA 20
9.29
SMA 50
8.23
Boll Upper
14.25
Boll Mid
9.29
Boll Lower
4.34
ATR 14
1.30
  • SMAs aligned bullish: 5 > 20 > 50 ($12.93 > $9.29 > $8.23), no bearish cross.
  • RSI 86.72 indicates overbought; momentum extreme, pullback risk.
  • MACD positive with histogram 0.31 confirms bullish momentum.
  • Price $15.05 above Bollinger upper $14.25 — expansion, statistically stretched.
  • 30-day range $6.52–$15.48; price at 94.2% of range, near top.

True Sentiment Analysis (Delta 40-60 Options)

From DNA_options_20261005_1651.json:

Call Volume: $997,160 (52.0%) Put Volume: $920,990 (48.0%) Total: $1,918,150

  • Sentiment: Balanced (call 52%, put 48%).
  • Call contracts 4,662 vs put 2,432; call trades 18 vs put 5 — more call activity but balanced dollar conviction.
  • Pure directional positioning suggests no strong near-term bias despite price surge.
  • Divergence: Technicals extremely bullish (RSI 86.72) but options flow neutral — caution on continuation.
Note: Options flow shows balanced delta-40-60 conviction, not confirming the rally.

Key Price Levels (Observational Only)

Support (SMA 5)
$12.93
Support (10-05 low)
$12.48
Resistance (30d high)
$15.48
Resistance (52w high)
$17.58

Interactive charts load with JavaScript. This text is the crawlable summary.